Acceso usuarios
Recientemente se han desarrollado nuevos bifosfonatos cada vez más potentes para el tratamiento de la osteoporosis posmenopáusica. El risedronato es un aminobifosfonato que ha mostrado una reducción del riesgo de fractura tanto vertebral como no vertebral y de cadera. Tiene aprobada su utilización en la osteoporosis posmenopáusica, en la osteoporosis esteroidea y del varón. Habitualmente es bien tolerado y se administra por vía oral una vez a la semana, si bien existen estudios que permitirán su utilización en una única dosis una vez al mes. El ácido zoledrónico también ha demostrado la capacidad de reducir del riesgo de fractura tanto vertebral como no vertebral y de cadera. Debe administrase por vía intravenosa, pero el intervalo de administración es de una vez al año, por lo que mejorará mucho el problema de la adherencia. Aún no tiene indicación para la osteoporosis del varón ni la esteroidea. Se uso será exclusivamente hospitalario. Ambos fármacos son muy eficaces, cómodos y seguros. La elección entre uno y otro dependerá de las propias circunstancias clínicas y de la opinión de cada paciente. Recently, every time more potent new bisphosphonates, have been developed for the treatment of postmneopausal osteoporosis. Risedronic acid is a aminobisphosphonate who has shown a reduction in the risk of vertebral fracture and also nonvertebral and hip fractures. It has been approved in Spain for its use in the treatment of postmenopausal osteoporosis and also male and glucocorticoid induced osteoporosis. Usually it is well tolerated and it is administered in a weekly oral dose. Zoledronic acid has also shown its capacity of reducing the risk of vertebral fracture and also nonvertebral and hip fractures It must be administered by intravenous inyection once a year. It has not been approved for its use in the treatment of postmenopausal osteoporosis and also male and glucocorticoid induced osteoporosis yet. It can be prescribed only in Hospitals. Both drugs are very safe, secure and valid for the treatment of osteoporosis. The election of one or another bisphosphonate depends on clinical circumstances and the opinion of every patient.
Recently, every time more potent new bisphosphonates, have been developed for the treatment of postmneopausal osteoporosis. Risedronic acid is a aminobisphosphonate who has shown a reduction in the risk of vertebral fracture and also nonvertebral and hip fractures. It has been approved in Spain for its use in the treatment of postmenopausal osteoporosis and also male and glucocorticoid induced osteoporosis. Usually it is well tolerated and it is administered in a weekly oral dose. Zoledronic acid has also shown its capacity of reducing the risk of vertebral fracture and also nonvertebral and hip fractures It must be administered by intravenous inyection once a year. It has not been approved for its use in the treatment of postmenopausal osteoporosis and also male and glucocorticoid induced osteoporosis yet. It can be prescribed only in Hospitals. Both drugs are very safe, secure and valid for the treatment of osteoporosis. The election of one or another bisphosphonate depends on clinical circumstances and the opinion of every patient.
